.Nature Medication, Posted online: 03 September 2024 doi:10.1038/ s41591-024-03223-zThis Point of view asks for introduction of individuals with MASLD and dimension of liver end results in cardio-- kidney-- metabolic trials, when data recommend mechanistically plausible advantages as well as professional safety-- as well as details factors to consider for trial concept as well as regulative commendation.